Aviamarin

General characteristics. Structure:

Active ingredient: 50 g of dimenhydrinatum.

Excipients: cellulose microcrystallic, povidone, кросповидон, Mannitolum, silicon dioxide colloid (aerosil), magnesium stearate.

Medicine from a motion desease.

Pharmacological properties:

Pharmacodynamics. Blocks histamine H1 receptors and m-holinoretseptory of the central nervous system. The vestibular mechanism of an inner ear oppresses, affecting first of all otoliths, in high doses — semicircular canals.

The main effect of dimenhydrinatum is implemented due to blockade of m-holinoretseptorov. Has antiemetic, sedative effect, eliminates dizziness.

Pharmacokinetics. After intake dimenhydrinatum is well soaked up, distributed on bodies and fabrics. Effect of drug is shown in 15-30 min. and remains during 3-6 h.

About 78% of dimenhydrinatum contact proteins of a blood plasma. Dimenhydrinatum is metabolized in a liver and almost completely brought out of an organism with urine within 24 hours. Small quantities are removed with breast milk. The elimination half-life of dimenhydrinatum makes about 3,5 hours.

Indications to use:

Sea and aeroembolism.

Prevention and treatment of symptoms of vestibular and labyrinth disturbances (dizziness, nausea, vomiting), except for the symptoms caused by antineoplastic therapy.

Symptomatic therapy of a disease of Menyer.

Route of administration and doses:

Inside, before food.

Sea and aeroembolism: for motion desease prevention the first dose should be accepted in 30-60 minutes prior to the movement.

Children at the age of 6-12 years: on 1/2-1 tablet (25-50 mg) each 6-8 hours, but no more than 3 tablets (150 mg) within 24 hours.

Adults and children of 12 years are also more senior: on 1-2 tablets (50-100 mg) each 4-6 hours, but no more than 8 tablets (400 mg) within 24 hours.

Prevention and treatment of symptoms of vestibular and labyrinth disturbances (dizziness, nausea, vomiting), except for the symptoms caused by antineoplastic therapy:

Children aged from 6-12 years: on 1/2-1 tablet (25-50 mg) each 6-8 hours, but no more than 3 tablets (150 mg) within 24 hours.

Adults and children are more senior than 12 years: on 1-2 tablets (50-100 mg) each 4-6 hours, but no more than 8 tablets (400 mg) within 24 hours.

Symptomatic therapy of a disease of Menyer: children aged from 6-12 years: on 1/2-1 tablet (25-50 mg) each 6-8 hours, but no more than 3 tablets (150 mg) within 24 hours.

Adults and children are more senior than 12 years: on 1-2 tablets (50-100 mg) each 4-6 hours, but no more than 8 tablets (400 mg) within 24 hours.

At advanced age drug should be accepted in the minimum dose recommended for adults.

Duration of use of drug and possibility of repetition of a course of treatment — in coordination with the doctor.

Features of use:

Use at pregnancy and during breastfeeding. Use of drug during pregnancy is possible only if the expected advantage for mother exceeds potential risk for a fruit. Use of drug during breastfeeding is contraindicated. In need of drug use, feeding by a breast should be stopped.

At use of dimenhydrinatum false-negative results of allergy tests are possible. Allergy tests should be carried out not earlier than in three days after the end of reception of dimenhydrinatum.

Dimenhydrinatum can show false increase in level of theophylline in blood at its definition by an immunological method.

Dimenhydrinatum can mask symptoms of ototoxicity and promote development of an irreversible hearing disorder in this connection its simultaneous use with ototoksichesky antibiotics is not recommended.

Dimenhydrinatum is metabolized in a liver in this connection it is necessary to be careful at use of drug for patients with a liver failure.

Influence on ability to manage vehicles and to be engaged in other types of activity

Considering side effect of dimenhydrinatum, it is necessary to be careful at control of vehicles and occupation potentially dangerous types of activity requiring special attention and speed of psychomotor reactions.

Side effects:

Frequency of development of undesirable reactions is presented as follows: very often (≥1/10 cases), it is frequent (≥1/100 and <1/10 cases), infrequently (≥1/1000 and <1/100 cases), is rare (≥1/10000 and <1/1000 cases) and is very rare (<1/10000 cases, including separate messages).

From the central nervous system: very often — dizziness, drowsiness, disturbance of concentration of attention; often — the general weakness, fatigue, concern, nervousness; seldom — a headache, sleeplessness.

From sense bodys: often - easing of night and color sight, a sight zatumanennost, accommodation disturbance.

From the alimentary system: often - dryness in a mouth, nausea, vomiting; very seldom — a loss of appetite.

From respiratory system: infrequently — a xeromycteria and throats, a condensation of a bronchial secret.

From cardiovascular system: seldom — a lowering of arterial pressure, tachycardia.

Allergic reactions: seldom - skin rash, medicamentous dermatitis; very seldom — a Quincke's disease, a bronchospasm.

From an urinary system: seldom — difficulty of an urination.
Other: seldom - hemolitic anemia.

If any of the undesirable reactions specified in the instruction are aggravated, or you noticed any other undesirable phenomena which are not specified in the instruction, report about it to the doctor.

Interaction with other medicines:

Dimenhydrinatum strengthens effect of atropine, tricyclic antidepressants, catecholamines, barbiturates, ethanol, sedative and hypnagogues, neuroleptics.

Dimenhydrinatum weakens action of corticosteroids, anticoagulants.

Dimenhydrinatum lowers reaction to Apomorphinum.

Dimenhydrinatum reduces depressive action of acetylcholine by a cardiac muscle.

The concomitant use of dimenhydrinatum with bismuth drugs, Scopolaminum, anesthetics and psychotropic drugs increases probability of a vision disorder.

Simultaneous use of drug with ototoksichesky antibiotics (streptomycin, Neomycinum, Viomycinum, amikacin, Kanamycinum) is not recommended as dimenhydrinatum can mask symptoms of ototoxicity and promote development of an irreversible hearing disorder.

Contraindications:

Hypersensitivity to dimenhydrinatum or other components of drug, children's age up to 6 years, the breastfeeding period.

With care. A convulsive syndrome, closed-angle glaucoma, a prostate hyperplasia, bronchial asthma, cardiovascular diseases, a hyperthyroidism, the stenosing round ulcer, piloroduodenalny obstruction and obstruction of a neck of a bladder.

Overdose:

Symptoms: dryness in a mouth, in a nose and in a throat, the face reddening which is slowed down and the complicated breath, confusion of consciousness, children have spasms, hallucinations.

At emergence of the specified symptoms it is necessary to see a doctor urgently.

Treatment: a gastric lavage a suspension of absorbent carbon (20-30 g), purpose of salt laxative (10-15 g of sodium of sulfate), symptomatic therapy, at spasms at children — phenobarbital (5-6 mg/kg), diazepam.

Storage conditions:

Period of validity - 2 years. Not to apply after the period of validity specified on packaging. To store in the dry, protected from light place at a temperature not above 25 °C. To store in the place, unavailable to children.

Issue conditions:

Without recipe

Packaging:

Tablets of 50 mg. On 5 or 10 tablets in a blister strip packaging from a film of the polyvinyl chloride and printing aluminum foil varnished. On 1, 2 blister strip packagings together with the application instruction place in a pack from a cardboard.